Replies to post #6400 on Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[forzagrifo]

patience is needed for this stock. Not many people know it yet especially with the derivative fair value changes and the change in distribution model that caused revenue to drop. All these are hiding the tremendous growth in the actual non-gaap adjusted net income.

Once we're uplisted in Nasdaq with more institutions and analyst coverage, this stock will surely be priced at fair value which is at least $20.